Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation
Werte in diesem Artikel
Oslo, October 31, 2024: Ultimovacs ASA ("Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third quarter 2024 results, on Wednesday, November 6, 2024.
The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Wednesday, November 6, 2024. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast.
The report and presentation will be available on the company website from 07:00 CET the same day.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Ausgewählte Hebelprodukte auf Ultimovacs AS Registered
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ultimovacs AS Registered
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu Ultimovacs AS Registered Shs
Analysen zu Ultimovacs AS Registered Shs
Keine Analysen gefunden.